12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Multimeric-001 Universal Flu Vaccine: Phase II data

The double-blind, Israeli Phase II BVX-005 trial in 120 elderly volunteers aged 65 and older showed that 2 doses of 500 µg Multimeric-001 Universal Flu Vaccine given 21 days apart were safe and well tolerated, which BiondVax said met the primary safety endpoint. The company...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >